Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug

Sanofi is licensing a RadioMedix radiopharmaceutical in development for neuroendocrine tumors. The French pharmaceutical giant is responsible for global commercialization of the therapy, a potential competitor to the Novartis radiopharmaceutical Lutathera. The post Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug appeared first on MedCity News.

Read More

Our Next Generations’ Health Depends on the Oral Health of Moms

This starts with viewing specialties such as oral health, maternal health, endocrinology, and cardiology — among others — as interconnected practices, not as separate areas. It also requires combining education, innovation, and investment to truly see — and feel — positive change and interconnected care The post Our Next Generations’ Health Depends on the Oral…

Read More

A Tailor-made Approach to Simplify Observational Research

A direct-to-patient model for observational research will ease the participation burden, better incorporate the patient voice, and empower individuals to take control of their health – all while meeting the growing demands for robust evidence in developing new drugs and therapeutics. The post A Tailor-made Approach to Simplify Observational Research appeared first on MedCity News.

Read More

Get Ready for HLTH 2024: A Preview Guide

HLTH 2024, scheduled for October 20-23 at the Venetian Expo Center in Las Vegas, will highlight new programming, a physicians roundtable, generative AI, the shifting landscapes of telemedicine, retail health, women’s health, and lots more. The post Get Ready for HLTH 2024: A Preview Guide appeared first on MedCity News.

Read More